Optimer files NDS for Dificid in Canada
Health Canada has granted Optimer priority review of the Dificid NDS, reducing the time to a potential regulatory approval in Canada. The NDS is based on the results
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.